1 results match your criteria: "Massachusetts6Harvard Medical School Center for Pall.[Affiliation]"
JAMA Intern Med
April 2014
The Dana Farber Cancer Center, Department of Psychosocial Oncology and Palliative Care, Boston, Massachusetts4Division of Aging, Brigham and Women's Hospital, Boston, Massachusetts5Ariadne Labs, Boston, Massachusetts6Harvard Medical School Center for Pall.
Strategically selecting patients for discussions and documentation about limiting life-sustaining treatments-choosing the right time along the end-of-life trajectory for such an intervention and identifying patients at high risk of facing end-of-life decisions-can have a profound impact on the value of advance care planning (ACP) efforts. Timing is important because the completion of an advance directive (AD) too far from or too close to the time of death can lead to end-of-life decisions that do not optimally reflect the patient's values, goals, and preferences: a poorly chosen target patient population that is unlikely to need an AD in the near future may lead to patients making unrealistic, hypothetical choices, while assessing preferences in the emergency department or hospital in the face of a calamity is notoriously inadequate. Because much of the currently studied ACP efforts have led to a disappointingly small proportion of patients eventually benefitting from an AD, careful targeting of the intervention should also improve the efficacy of such projects.
View Article and Find Full Text PDF